STOCK TITAN

[Form 4] Wayfair Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Very Negative)
Form Type
4
Rhea-AI Filing Summary

Form 4 insider activity – ClearPoint Neuro, Inc. (CLPT)

Chief Business Officer Jeremy L. Stigall purchased 1,608 shares of ClearPoint Neuro common stock on 06/30/2025 through the company’s Employee Stock Purchase Plan (ESPP). The acquisition price was $10.15, reflecting the ESPP’s 15 % discount to the lower of the market prices on the first or last day of the six-month purchase period (01/01/2025-06/30/2025). After the transaction, Stigall directly owns 72,355 CLPT shares.

No shares were sold and no derivative securities were involved. While the purchase is modest in size, insider buying—especially by a senior officer—tends to be interpreted as a sign of management’s confidence in the company’s prospects, albeit with limited immediate financial impact.

Attività interna Modulo 4 – ClearPoint Neuro, Inc. (CLPT)

Il Chief Business Officer Jeremy L. Stigall ha acquistato 1.608 azioni di azioni ordinarie ClearPoint Neuro il 30/06/2025 tramite il Piano di Acquisto Azionario per Dipendenti (ESPP) della società. Il prezzo di acquisto è stato di 10,15 $, riflettendo lo sconto del 15% previsto dall'ESPP sul prezzo di mercato più basso tra il primo e l'ultimo giorno del periodo di acquisto di sei mesi (01/01/2025-30/06/2025). Dopo la transazione, Stigall possiede direttamente 72.355 azioni CLPT.

Non sono state vendute azioni né coinvolti strumenti derivati. Sebbene l'acquisto sia di entità modesta, l'acquisto da parte di un dirigente interno è spesso interpretato come un segnale di fiducia della dirigenza nelle prospettive dell'azienda, anche se con un impatto finanziario immediato limitato.

Actividad interna Formulario 4 – ClearPoint Neuro, Inc. (CLPT)

El Director de Negocios Jeremy L. Stigall compró 1,608 acciones de acciones ordinarias de ClearPoint Neuro el 30/06/2025 a través del Plan de Compra de Acciones para Empleados (ESPP) de la compañía. El precio de adquisición fue de $10.15, reflejando el descuento del 15 % del ESPP aplicado al precio de mercado más bajo entre el primer o último día del período de compra de seis meses (01/01/2025-30/06/2025). Tras la operación, Stigall posee directamente 72,355 acciones CLPT.

No se vendieron acciones ni se utilizaron valores derivados. Aunque la compra es modesta, las compras internas, especialmente por parte de un alto ejecutivo, suelen interpretarse como una señal de confianza de la dirección en las perspectivas de la empresa, aunque con un impacto financiero inmediato limitado.

폼 4 내부자 거래 – ClearPoint Neuro, Inc. (CLPT)

최고사업책임자 Jeremy L. Stigall은 2025년 6월 30일 회사의 직원 주식 구매 계획(ESPP)을 통해 1,608주의 ClearPoint Neuro 보통주를 매입했습니다. 매입 가격은 10.15달러로, 6개월 구매 기간(2025년 1월 1일~6월 30일) 첫날 또는 마지막 날 중 낮은 시장 가격에 ESPP의 15% 할인율이 적용된 금액입니다. 거래 후 Stigall은 직접 72,355주의 CLPT 주식을 보유하게 되었습니다.

주식 매도나 파생상품 거래는 없었습니다. 매입 규모는 크지 않지만, 특히 고위 임원의 내부자 매입은 경영진이 회사의 전망에 대해 신뢰하고 있음을 나타내는 신호로 해석되는 경우가 많으며, 즉각적인 재무 영향은 제한적입니다.

Activité d’initié Formulaire 4 – ClearPoint Neuro, Inc. (CLPT)

Le Chief Business Officer Jeremy L. Stigall a acheté 1 608 actions ordinaires de ClearPoint Neuro le 30/06/2025 via le Plan d’Achat d’Actions des Employés (ESPP) de l’entreprise. Le prix d’acquisition était de 10,15 $, reflétant la remise de 15 % du plan ESPP sur le prix de marché le plus bas entre le premier et le dernier jour de la période d’achat de six mois (01/01/2025-30/06/2025). Après la transaction, Stigall détient directement 72 355 actions CLPT.

Aucune action n’a été vendue et aucun instrument dérivé n’a été impliqué. Bien que l’achat soit modeste, l’acquisition par un cadre supérieur est souvent interprétée comme un signe de confiance de la direction dans les perspectives de l’entreprise, même si l’impact financier immédiat reste limité.

Formular 4 Insider-Aktivität – ClearPoint Neuro, Inc. (CLPT)

Chief Business Officer Jeremy L. Stigall erwarb am 30.06.2025 1.608 Aktien der ClearPoint Neuro Stammaktien über den Mitarbeiter-Aktienkaufplan (ESPP) des Unternehmens. Der Erwerbspreis betrug 10,15 $ und entspricht dem 15 % Rabatt des ESPP auf den niedrigeren Marktpreis am ersten oder letzten Tag des sechsmonatigen Kaufzeitraums (01.01.2025–30.06.2025). Nach der Transaktion besitzt Stigall direkt 72.355 CLPT-Aktien.

Es wurden keine Aktien verkauft und keine Derivate verwendet. Obwohl der Kaufumfang gering ist, wird Insider-Kauf – insbesondere durch einen leitenden Angestellten – oft als Zeichen für das Vertrauen des Managements in die Aussichten des Unternehmens gewertet, wenn auch mit begrenzter unmittelbarer finanzieller Auswirkung.

Positive
  • Insider purchase: Chief Business Officer acquired 1,608 shares, boosting direct ownership to 72,355 and signaling incremental management confidence.
Negative
  • None.

Insights

TL;DR: Small ESPP buy; positive signal but immaterial to fundamentals.

Stigall’s 1,608-share purchase marginally increases his stake, taking advantage of the standard 15 % ESPP discount. The filing shows no sales or option exercises, implying a net commitment of capital. Although insider buying is directionally constructive—especially from a C-suite executive—the dollar value and share count are too small to alter valuation models or liquidity. The event is best viewed as a mild vote of confidence rather than a catalyst.

Attività interna Modulo 4 – ClearPoint Neuro, Inc. (CLPT)

Il Chief Business Officer Jeremy L. Stigall ha acquistato 1.608 azioni di azioni ordinarie ClearPoint Neuro il 30/06/2025 tramite il Piano di Acquisto Azionario per Dipendenti (ESPP) della società. Il prezzo di acquisto è stato di 10,15 $, riflettendo lo sconto del 15% previsto dall'ESPP sul prezzo di mercato più basso tra il primo e l'ultimo giorno del periodo di acquisto di sei mesi (01/01/2025-30/06/2025). Dopo la transazione, Stigall possiede direttamente 72.355 azioni CLPT.

Non sono state vendute azioni né coinvolti strumenti derivati. Sebbene l'acquisto sia di entità modesta, l'acquisto da parte di un dirigente interno è spesso interpretato come un segnale di fiducia della dirigenza nelle prospettive dell'azienda, anche se con un impatto finanziario immediato limitato.

Actividad interna Formulario 4 – ClearPoint Neuro, Inc. (CLPT)

El Director de Negocios Jeremy L. Stigall compró 1,608 acciones de acciones ordinarias de ClearPoint Neuro el 30/06/2025 a través del Plan de Compra de Acciones para Empleados (ESPP) de la compañía. El precio de adquisición fue de $10.15, reflejando el descuento del 15 % del ESPP aplicado al precio de mercado más bajo entre el primer o último día del período de compra de seis meses (01/01/2025-30/06/2025). Tras la operación, Stigall posee directamente 72,355 acciones CLPT.

No se vendieron acciones ni se utilizaron valores derivados. Aunque la compra es modesta, las compras internas, especialmente por parte de un alto ejecutivo, suelen interpretarse como una señal de confianza de la dirección en las perspectivas de la empresa, aunque con un impacto financiero inmediato limitado.

폼 4 내부자 거래 – ClearPoint Neuro, Inc. (CLPT)

최고사업책임자 Jeremy L. Stigall은 2025년 6월 30일 회사의 직원 주식 구매 계획(ESPP)을 통해 1,608주의 ClearPoint Neuro 보통주를 매입했습니다. 매입 가격은 10.15달러로, 6개월 구매 기간(2025년 1월 1일~6월 30일) 첫날 또는 마지막 날 중 낮은 시장 가격에 ESPP의 15% 할인율이 적용된 금액입니다. 거래 후 Stigall은 직접 72,355주의 CLPT 주식을 보유하게 되었습니다.

주식 매도나 파생상품 거래는 없었습니다. 매입 규모는 크지 않지만, 특히 고위 임원의 내부자 매입은 경영진이 회사의 전망에 대해 신뢰하고 있음을 나타내는 신호로 해석되는 경우가 많으며, 즉각적인 재무 영향은 제한적입니다.

Activité d’initié Formulaire 4 – ClearPoint Neuro, Inc. (CLPT)

Le Chief Business Officer Jeremy L. Stigall a acheté 1 608 actions ordinaires de ClearPoint Neuro le 30/06/2025 via le Plan d’Achat d’Actions des Employés (ESPP) de l’entreprise. Le prix d’acquisition était de 10,15 $, reflétant la remise de 15 % du plan ESPP sur le prix de marché le plus bas entre le premier et le dernier jour de la période d’achat de six mois (01/01/2025-30/06/2025). Après la transaction, Stigall détient directement 72 355 actions CLPT.

Aucune action n’a été vendue et aucun instrument dérivé n’a été impliqué. Bien que l’achat soit modeste, l’acquisition par un cadre supérieur est souvent interprétée comme un signe de confiance de la direction dans les perspectives de l’entreprise, même si l’impact financier immédiat reste limité.

Formular 4 Insider-Aktivität – ClearPoint Neuro, Inc. (CLPT)

Chief Business Officer Jeremy L. Stigall erwarb am 30.06.2025 1.608 Aktien der ClearPoint Neuro Stammaktien über den Mitarbeiter-Aktienkaufplan (ESPP) des Unternehmens. Der Erwerbspreis betrug 10,15 $ und entspricht dem 15 % Rabatt des ESPP auf den niedrigeren Marktpreis am ersten oder letzten Tag des sechsmonatigen Kaufzeitraums (01.01.2025–30.06.2025). Nach der Transaktion besitzt Stigall direkt 72.355 CLPT-Aktien.

Es wurden keine Aktien verkauft und keine Derivate verwendet. Obwohl der Kaufumfang gering ist, wird Insider-Kauf – insbesondere durch einen leitenden Angestellten – oft als Zeichen für das Vertrauen des Managements in die Aussichten des Unternehmens gewertet, wenn auch mit begrenzter unmittelbarer finanzieller Auswirkung.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Conine Steven

(Last) (First) (Middle)
C/O WAYFAIR INC., 4 COPLEY PLACE

(Street)
BOSTON MA 02116

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Wayfair Inc. [ W ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
Co-Founder
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 06/30/2025 S(1) 21,963 D $52.01(2) 417,110 D
Class A Common Stock 07/01/2025 S(1) 142,870 D $52.38(3) 274,240 D
Class A Common Stock 07/01/2025 S(1) 38,073 D $53.36(4) 236,167 D
Class A Common Stock 22,857 I See Footnote(5)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2024.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.00 to $52.11, inclusive. The reporting person undertakes to provide to Wayfair Inc., any security holder of Wayfair Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.00 to $52.99, inclusive. The reporting person undertakes to provide to Wayfair Inc., any security holder of Wayfair Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.00 to $53.74, inclusive. The reporting person undertakes to provide to Wayfair Inc., any security holder of Wayfair Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
5. Represents shares directly owned by SK Ventures LLC, of which the reporting person is a member and may be deemed to be a beneficial owner.
Remarks:
/s/ Enrique Colbert, Attorney-in-Fact for Steven Conine 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ClearPoint Neuro's Form 4 filed on 07/02/2025 report?

It disclosed that Chief Business Officer Jeremy L. Stigall bought 1,608 CLPT shares on 06/30/2025 through the ESPP.

How many CLPT shares did Jeremy L. Stigall purchase?

Stigall purchased 1,608 common shares.

At what price were the ESPP shares acquired?

The shares were bought at $10.15, the ESPP’s 15 % discount price.

What is Stigall's total share ownership after the transaction?

Following the purchase, he directly owns 72,355 CLPT shares.

Did the filing report any sale of ClearPoint Neuro shares?

No. The Form 4 shows only an acquisition; there were no dispositions.

Why is the purchase price discounted under the ESPP?

The ESPP allows employees to buy shares at 85 % of the lower of the market price on the first or last day of the purchase period.
Wayfair Inc

NYSE:W

W Rankings

W Latest News

W Latest SEC Filings

W Stock Data

6.50B
95.15M
5.19%
110.41%
14.16%
Internet Retail
Retail-catalog & Mail-order Houses
Link
United States
BOSTON